Cargando…

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

In respiratory syncytial virus (RSV) disease the balance between the innate and adaptive immune responses determines the expression of the pathological phenotype favoring the development of acute bronchiolitis, and in certain children the development of recurrent wheezing. While humoral antibody pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mejías, Asunción, Ramilo, Octavio
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721379/ https://www.ncbi.nlm.nih.gov/pubmed/19707374

Ejemplares similares

2783. Expansion of Monocytic Myeloid-Derived Suppressor Cells in Infants with Severe Respiratory Syncytial Virus (RSV) Infection
por: Bedoya, Santiago Acero, et al.
Publicado: (2019)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Respiratory Syncytial Virus (RSV)–Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants
por: Koivisto, Karoliina, et al.
Publicado: (2021)

131. The Protective Role of Mucosal Interferons in Infants with Respiratory Syncytial Virus (RSV) Infection
por: Taveras, Jeanette, et al.
Publicado: (2020)

79. Mucosal Interferon (IFN) Responses in Infants with Respiratory Syncytial Virus (RSV) Infection to Inform Live Attenuated Vaccine (LAV) Development
por: Taveras, Jeanette, et al.
Publicado: (2019)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

1186. Increased Respiratory Syncytial Virus (RSV) Viral Replication Leads to Increased Cytokine Production and Polarized Interferon Response in Infant Mucosal Epithelium
por: Glowinski, Rebecca M, et al.
Publicado: (2021)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

118. Nasopharyngeal (NP) Bacterial Detection in Infants With Respiratory Syncytial Virus (RSV) Infection: Impact on Clinical Outcomes
por: Diaz, Alejandro, et al.
Publicado: (2018)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

2352. Increased on Childhood Recurrent Wheezing and Asthma After Respiratory Syncytial Viral (RSV) Infection in Full-Term Infants
por: Mejias, Asuncion, et al.
Publicado: (2018)

Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
por: Mejías, Asunción, et al.
Publicado: (2007)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Respiratory Syncytial Virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice
por: Torres, Juan Pablo, et al.
Publicado: (2010)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
por: Al Aql, Fahad, et al.
Publicado: (2016)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Viral Load Dynamics and Clinical Disease Severity in Infants With Respiratory Syncytial Virus Infection
por: Garcia-Mauriño, Cristina, et al.
Publicado: (2019)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
por: Claydon, Jennifer, et al.
Publicado: (2017)

1465. Age-Dependent Interactions Among Clinical Characteristics, Viral Loads and Disease Severity in Young Children with Respiratory Syncytial Virus Infection (RSV) Infection
por: Brenes-Chacon, Helena, et al.
Publicado: (2020)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
por: Fernández, Pilar, et al.
Publicado: (2010)

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
por: Forbes, Michael L, et al.
Publicado: (2014)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines
por: King, Tiffany, et al.
Publicado: (2021)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
por: Elhalik, M., et al.
Publicado: (2019)

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2014)

A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
por: Bentley, Anthony, et al.
Publicado: (2013)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Respiratory Syncytial Virus bronchiolitis: Impact of second-hand smoke exposure on immune profiles
por: Diaz, Alejandro, et al.
Publicado: (2017)

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands
por: Whelan, Barbara, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t2jivhvbupd5vrcsegbonbkg1o